HealthCare Global Enterprises Limited has reported its financial results for the quarter and fiscal year ended March 31, 2026. The company recorded an annual revenue of ₹1,359.37 crore and a consolidated net profit of ₹22.78 crore for the year. Furthermore, the Board approved the divestment of its 100% equity stake in BACC Health Care Private Limited to Inviga Healthcare Fund I for ₹37.64 crore, marking a strategic shift away from non-core fertility services.
Financial Performance Overview
For the fiscal year ended March 31, 2026, HealthCare Global Enterprises reported consolidated revenue of ₹2,538.43 crore, compared to ₹2,218.14 crore in the previous year. The consolidated net profit for the year stood at ₹22.78 crore. For the quarter ending March 31, 2026, the company achieved consolidated revenue of ₹650.29 crore and a quarterly net profit of ₹4.04 crore.
Strategic Divestment
The Board of Directors has approved the sale of the company’s entire shareholding in BACC Health Care Private Limited to Inviga Healthcare Fund I for a total consideration of ₹37.64 crore. This decision aligns with the company’s objective to streamline its operations by exiting the fertility and reproductive healthcare sector, which is deemed a non-core business activity. The divestment includes an upfront payment of ₹28.23 crore, with the remaining ₹9.41 crore payable within 18 months.
Rights Issue and Capital Expansion
During the quarter ending March 31, 2026, the company successfully completed a rights issue, allotting 8,294,566 fully paid-up equity shares at an issue price of ₹512 per share. This initiative raised significant capital, with ₹416.39 crore added to the securities premium reserve. The company intends to utilize these proceeds for growth and strategic objects as outlined in the Letter of Offer.
Leadership and Governance Updates
The company announced several key leadership changes effective May 25, 2026. Mr. Sanjeev Kumar has been appointed as the new Chief Financial Officer and Key Managerial Personnel. Additionally, Mr. Rajiv Maliwal was re-appointed as a Non-Executive Independent Director for a second five-year term. In other operational updates, Mr. Ravi Gothwal has been appointed as AVP – Investor Relations, and Mr. Vijay S. Shanbhag has been re-appointed as the Internal Auditor for a one-year term effective May 30, 2026.
Source: BSE